PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Posttranslational modifications to the intracellular domain of the EGFR are known to regulate EGFR functions; however, modifications to the extracellular domain and their effects remain relatively unexplored. Here, we determined that methylation at R198 and R200 of the EGFR extracellular domain by protein arginine methyltransferase 1 (PRMT1) enhances binding to EGF and subsequent receptor dimerization and signaling activation. In a mouse orthotopic colorectal cancer xenograft model, expression of a methylation-defective EGFR reduced tumor growth. Moreover, increased EGFR methylation sustained signaling activation and cell proliferation in the presence of the therapeutic EGFR monoclonal antibody cetuximab. In colorectal cancer patients, EGFR methylation level also correlated with a higher recurrence rate after cetuximab treatment and reduced overall survival. Together, these data indicate that R198/R200 methylation of the EGFR plays an important role in regulating EGFR functionality and resistance to cetuximab treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, methylation at R198 and R200 of the EGFR ECD plays an essential role in regulating EGFR functionality and resistance to cetuximab treatment in CRC patients [145].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [145]
In the citing paper
“In addition, R198/R200 methylation and mutation in the kinase domain of EGFR (V843I) correlated with disease progression in the presence of cetuximab [69].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118 · cited 1×
“Upon binding, cetuximab occludes the EGF-binding site and prevents EGFR from adopting the active conformation required for ligand binding and dimerization (47).”
BackgroundProtein arginine methyltransferases and cancer
Yang, Y., & Bedford, M. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3409 · Cited by 1,083 · cited 1×
“During arginine methylation, PRMTs transfer methyl groups from S-adenosylmethionine (SAM) to the guanidine nitrogen of specific arginine residues on their target proteins, which in turn alter the protein structure, protein-protein interaction, protein localization, and enzyme activity that are critical for various cel…”
BackgroundDe Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain Dimerization
Ferguson, K. M., Berger, M. B., Mendrola, J. M., Cho, H.-S., Leahy, D. J., & Lemmon, M. A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00047-9 · Cited by 801
Research works printed but not linked: 1
- E-mail: mhung@mdanderson.org. jci.org Volume 125 Number 12 December 2015 activity. Cell Cycle. 2005;4(12):1834-1841.
Cited by
Items 101–156 of 156
Wnt2 Contributes to the Development of Atherosclerosis
Zhang, J., Rojas, S., Singh, S., Musich, P. R., Gutierrez, M., Yao, Z., Thewke, D. P., & Jiang, Y. Q. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.751720 · Cited by 12
“Several recent studies have suggested that a link between the endothelial-to-mesenchymal transition (EndMT) and the activation of endothelial TGF-β signaling may be an important driver of atherogenesis (4, 5).”
BackgroundProtein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities
Jeong, Y., Cho, Y., & Kim, Y. K. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01240-3 · Cited by 12
“…via release from nucleolus [262] Colorectal cancer High Oncogenic EGFR methylation (R198/R200) enhances EGF signaling and cetuximab resistance [111] H4R3me2a recruits SMARCA4 to activate EGFR/TNS4 signaling, promoting cancer progression [69] NONO methylation (R251) promotes colorectal cancer…”
Bhandari, K., & Ding, W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073958 · Cited by 10
“Its involvement in other cancer types, such as lung cancer [98] and colorectal cancer [99], is also reported.”
BackgroundArginine methylation in cancer: mechanisms and therapeutic implications
Xu, Y., Wu, Q., Zhang, Y., Gu, Y., Zhu, H., Fu, X., Li, A., & Li, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00860-5 · Cited by 14
“In CRC, it methylates EGFR at R198/ R200 in the extracellular domain, enhancing ligand binding and receptor activation to drive tumor cell proliferation [283].”
An essential role of PRMT1-mediated EGFR methylation in EGFR activation by ribonuclease 5.
Wang, W., Hsu, J.-M., Wang, Y., Lee, H., Yamaguchi, H., Liao, H.-W., & Hung, M. (2019) · Europe PMC (PubMed Central) · Cited by 10
Self-citationSecomandi, E., Salwa, A., Vidoni, C., Ferraresi, A., Follo, C., & Isidoro, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094782 · Cited by 13
Recognition Receptor for Methylated Arginine at the Single Molecular Level
Cao, X., Guo, Y., Feng, Y., Liu, X., Yao, F., Chen, T., Tian, L., & Kang, X. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c00406 · Cited by 10
PRMT1 and PRMT5: on the road of homologous recombination and non-homologous end joining
Yin, S., Liu, L., & Gan, W. (2022) · Genome Instability & Disease · doi:10.1007/s42764-022-00095-w · Cited by 12
“, 2021; Lorton & Shechter, 2019), cell signaling (Albrecht et al., 2018; Feng et al., 2019; Geoghegan et al., 2015; Liao et al., 2015; Yin et al., 2021), and DNA repair (Auclair & Richard, 2013; Brobbey et al.”
BackgroundTargeting non-histone methylation in gastrointestinal cancers: From biology to clinic
Sun, Z., Liu, L., & Chen, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116802 · Cited by 8
Jing, W., Bi, Y., Wang, G., Zeng, S., Han, L., Yang, H., Wang, N., & Zhao, Y. (2020) · Lipids · doi:10.1002/lipd.12281 · Cited by 8
Tao, M., Shi, Y., Chen, H., Li, J., Wang, Y., Ma, X., Du, L., Wang, Y., Yang, X., Hu, Y., et al. (2024) · Molecular Biomedicine · doi:10.1186/s43556-023-00161-z · Cited by 8
“PRMT1 was capable of catalyzing the methylation of R198/200 residues in the extracellular domain of EGFR, thereby enhancing its affinity for EGF and promoting EGFR homodimerization [44].”
Self-citationMicallef, I., Fenech, K., & Baron, B. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1455415 · Cited by 8
Li, X., Zhao, Z., Yi, S., Ma, L., Li, M., Liu, M., Zhang, Y., & Liu, G. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1561-0 · Cited by 7
Ali, M. A., Zahra, O. S., Morsi, M. I., Safwany, M. M. E., & Feky, S. E. E. (2024) · EJNMMI Reports · doi:10.1186/s41824-024-00233-5 · Cited by 7
Arginine Methylation by PRMT1 Affects ADAMTS13 Secretion and Enzymatic Activity
Liu, S., Ma, M., Qu, J., Muia, J., Wu, Z., Bonnez, Q., Vanhoorelbeke, K., Zheng, L., Zhao, X., & Zheng, X. L. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322249 · Cited by 6
Hsieh, C.-Y., Chang, W., Lin, C., Chen, J.-H., Lin, C., Liu, C., Chen, L., & Hung, M. (2022) · PubMed · Cited by 7
Self-citationChou, C., Liu, Y., Chen, Y., Huang, P., Tsou, P.-H., Chen, C., Lee, H., Wang, Y., Hsu, J. L., Lee, J.-F., et al. (2020) · ACS Sensors · doi:10.1021/acssensors.9b01736 · Cited by 6
Self-citationWang, Y., Ma, C., Liu, X., Cheng, J., Zhu, D., Liu, P., Qi, P., Li, X., Gu, J., & Wang, Q. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118590 · Cited by 7
Self-citationTudor-based proteomic strategy pan-specifically enriches and identifies protein arginine methylation
Lu, L., Li, T., Zhang, R., Wang, Y., Ye, X.-P., Luo, Y., Sun, L., Qi, L., Ye, Z., Mao, Y., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00599-y · Cited by 6
“PRMT1, the primary enzyme for aDMA modi fi cation, methylates arginine residues in EGFR (Liao et al, 2015), EZH2 (Li et al, 2020), SMAD4 (Albrecht et al, 2018) and CDK4 (Dolezal et al, 2017), whose sites exhibit limited sequence conservation.”
Self-citationIL-22BP controls the progression of liver metastasis in colorectal cancer
Giannou, A. D., Kempski, J., Zhang, T., Lücke, J., Shiri, A. M., Zazara, D. E., Belios, I., Machicote, A., Seeger, P., Agalioti, T., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1170502 · Cited by 4
“The mice were sacrificed after 4 weeks and liver macroscopic metastases were counted by using a stereoscope (31).”
MethodAkbari, B., Hasan, M. M., & Islam, S. M. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2520306 · Cited by 9
Influence of human HB-EGF secreted form on cells with different EGFR and ErbB4 quantity
Krynina, O. I., Korotkevych, N. V., Labyntsev, А. J., Романюк, С. И., Колибо, Д. В., & Комісаренко, С. В. (2019) · The Ukrainian Biochemical Journal · doi:10.15407/ubj91.05.025 · Cited by 4
“The interaction of the EGF receptor with a ligand and its activation can be affected by specific antagonists, for example, the recently described glycoprotein MIF that is capable of blocking EGFR activation [21] or by the processes of receptor methylation, that facilitate high-affinity ligand binding [22].”
BackgroundSandoval, C., Torrens, F., Godoy, K., Reyes, C., & Farías, J. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512258 · Cited by 5
“PRMT1 methylates not just histones but also proteins, including RUNX1 and EGFR, and has been linked to processes as varied as cell proliferation, survival, and differentiation [5,8,9].”
BackgroundTherapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy
Chiu, P.-H., Lai, K.-C., Wang, H.-L., Chang, Y.-W., Wu, W.-C., Chen, T.-H., Tsai, Y., Song, J.-H., Sun, N.-Y., Chau, G., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102448 · Cited by 7
“For TNF-α , our previous work and other studies have demonstrated that EMT confers cetuximab resistance 21,22,39 ; the EMT transcriptional factor Snail induces TNF-α that promotes tumor-related inflammation and boosts EMT.”
Self-citationChen, S., Dai, Z., Shi, J., Rui, M., Zhang, Z., & Xu, Q. (2025) · International Journal of Oral Science · doi:10.1038/s41368-025-00396-2 · Cited by 5
“#HY-124329A, MCE, China) as a cross-linking agent following the protocols described in literature 53 .”
Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment.
Korphaisarn, K., Chou, C., Xia, W.-Y., Clarke, C. N., Katkhuda, R., Davis, J. S., Raghav, K. P. S., Liao, H.-W., Wu, J. Y., Menter, D. G., et al. (2017) · PubMed · Cited by 5
Self-citationCirculating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients
Petrillo, A., Salati, M., Trapani, D., & Ghidini, M. (2020) · Current Drug Targets · doi:10.2174/1389450121999201103194248 · Cited by 5
Signal Transduction Inhibitors
Rönnberg, H. (2023) · CABI eBooks · doi:10.1079/9781789245820.0006 · Cited by 3
Dronko, L. M., Lutsenko, T. M., Korotkevych, N. V., Vovk, I. O., Zhukova, D., Романюк, С. И., Siromolot, A. A., Labyntsev, А. J., & Колибо, Д. В. (2024) · The Ukrainian Biochemical Journal · doi:10.15407/ubj96.05.005 · Cited by 3
Hedgehog signaling in cutaneous squamous cell carcinoma
Pyczek, J. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6687 · Cited by 2
Research Progress of Protein Arginine Methyltransferase 1 Inhibitors in the Treatment of Antitumor
朱, 照. (2022) · Pharmacy Information · doi:10.12677/pi.2022.112014 · Cited by 1
Modern Approaches to Anti-EGFR Therapy
Владимировна, Д. Е., Nadyrova, A. I., Luginskaya, S., Kosnyrev, A. S., Владимировна, У. В., & Ilinskaya, O. N. (2025) · Molecular Biology · doi:10.1134/s0026893325700347 · Cited by 1
“Methylation of the R198/R200 residues and the V843I mutation of the kinase domain of EGFR correlate with disease progression in patients treated with cetuximab [33].”
Multiomics Research Strategies in Cancer: A Growing and Innovative Field
Du, Z., Liu, X., Lv, Z., Wang, B., Xia, Y., Al-duais, W. A. M., Yan, L., Zhang, F., & Li, Y. (2026) · MedComm · doi:10.1002/mco2.70644 · Cited by 2
Mutlu, M., Mutlu, P., Azarkan, S. Y., Bayır, Ö., Öcal, B., Saylam, G., & Korkmaz, M. (2020) · Balkan Journal of Medical Genetics · doi:10.2478/bjmg-2020-0025 · Cited by 1
“In some of the studies, the relationship between methylated EGFR protein and HNSCC was shown [26,27].”
BackgroundKokoropoulos, P., Christodoulou, S., Tsiakanikas, P., Vassiliu, P., Kontos, C. K., & Arkadopoulos, N. F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146683 · Cited by 1
“PRMT1 is a well-characterized oncoprotein in CRC driving epidermal growth factor receptor ( EGFR ) activation via arginine methylation and conferring cetuximab resistance [32].”
The Role of Protein Arginine Methyltransferase 1 in Gastrointestinal Cancers
Zou, J., Shen, W., Zhang, Y., & Ying, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96197 · Cited by 1
Investigating epigenetic therapies and combinations for the treatment of cancers
O’Brien, S. W. (2023) · Digital Repository Service (Northeastern University) · doi:10.17760/d20620610 · Cited by 1
Hot off the press: downregulation of PRMT1 for long-lasting effects of bronchial thermoplasty
Rahmawati, S. F., & Gosens, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01898-2019
Investigational new drugs against glioblastoma
Kamson, D. O., Khela, H. S., & Laterra, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00002-6 · Cited by 1
Wang, J., Yang, R., Cheng, Y., Zhou, Y., Zhang, T., Wang, S., Li, H., Jiang, W., & Zhang, X. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3988394
Qiao, Z., Li, Y., Cheng, Y., Liu, S., & Li, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3291514/v1 · Cited by 1
Xu, Z., Ye, C., Cheng, Y., Zhao, F., Li, J., Jiang, J., & Liu, S. (2025) · Research Square · doi:10.21203/rs.3.rs-3291514/v2
Liu, D., Wang, Q., Zhang, R., Su, R., Zhang, J., Liu, S., Li, H., Chen, Z., Zhang, Y., De, K., et al. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60956-3
Yao, B., Gui, T., Zeng, X., Deng, Y., Wang, Z., Wang, Y., Yang, D., Li, Q., Xu, P., Hu, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14423343
Self-citationYang, L., Bhattacharya, A., Li, Y., Sexton, S., Ling, X., Fengzhi, L. I., & Zhang, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19959954
Yao, B., Gui, T., Zeng, X., Deng, Y., Wang, Z., Wang, Y., Yang, D., Li, Q., Xu, P., Hu, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14423346
Self-citationYao, B., Gui, T., Zeng, X., Deng, Y., Wang, Z., Wang, Y., Yang, D., Li, Q., Xu, P., Hu, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14423349
Self-citationYu, S., Li, J., Wu, X., Lu, S., Li, C., Cheng, H., Guo, H., Yang, P., & Wang, L. (2026) · Medicine · doi:10.1097/md.0000000000047306
“[41] This provides a basis for the study of EGFR modification in the improvement of myocardial injury in T2DM complicated with CHD. Based on network pharmacology analysis and molecular docking results, SGLT2is have been shown to have strong binding affinity with target proteins EGFR, ITGB2, and LCK.”
Crosstalk between IGF-1 and estrogen receptor non-genomic signaling pathway in breast cancer
Choucair, A. (2018) · theses.fr (ABES) · doi:10.70675/f47f4849zf8f2z41a1za5cfzf76d365b59bb · Cited by 2
The role of PRMT5-mediated methylation of steroid receptor in breast Cancer
Pham, T. H. (2022) · theses.fr (ABES) · doi:10.70675/f6e3d282z871dz4ffaz87bazb04f22d60d50 · Cited by 1
Suresh, S. (2021) · theses.fr (ABES) · doi:10.70675/d0ca1237zb08dz4dbfz9d33zd98df750e43c · Cited by 1
Investigating PRMT5 functions in triple-negative breast cancers
Dakroub, R. (2023) · theses.fr (ABES) · doi:10.70675/26c4b7a4z8cc8z4e04za75dz529e8665ff1a · Cited by 1
Khan, S. N., Ahmad, A., & Siddiqui, M. H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1841266
Kwon, S. H., & Lee, J. M. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70322 · Cited by 1
“Since different types of PRMTs generate distinct methy-larginine products while sharing the same methyl-donor economy, PRMT-dependent regulation may involve competition and compensation among enzyme pathways rather than isolated substrate selection alone.”
Metadata
- Authors
- Liao, H.-W., Hsu, J.-M., Xia, W., Wang, H.-L., Wang, Y.-N., Chang, W.-C., Arold, S. T., Chou, C.-K., Tsou, P.-H., Yamaguchi, H., Fang, Y.-F., Lee, H.-J., Lee, H.-H., Tai, S.-K., Yang, M.-H., Morelli, M. P., Sen, M., Ladbury, J. E., Chen, C.-H., Grandis, J. R., Kopetz, S., & Hung, M.-C.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- China Medical University (TW)
- Taipei Veterans General Hospital (TW)
- National Yang Ming University (TW)
- University of Pittsburgh (US)
- University of Leeds (GB)
- Genomics Research Center, Academia Sinica (TW)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-11-16
- Volume
- 125
- Issue
- 12
- Pages
- 4529-4543
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC4665782
- OpenAlex
- W2176390318
- Cited by
- 155
- References
- 60
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 15 · 2023: 15 · 2022: 12 · 2021: 24 · 2020: 19 · 2019: 16 · 2018: 11 · 2017: 15 · 2016: 8 · 2015: 1
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- King Abdullah University of Science and Technology Repository (King Abdullah University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (CCSG CA 16672, CA 016672, CA109311, R01CA109311, P01CA099031, P30CA016672, P50CA097190, CA 099031)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- EGFR, PRMT1, arginine methylation, cetuximab resistance, EGFR signaling, receptor dimerization, colorectal cancer, tumor recurrence, overall survival, monoclonal antibody therapy
- MeSH terms
- Cetuximab, Animals, Colonic Neoplasms, Female, Humans, Methylation, Mice, Nude, Neoplasm Transplantation, Protein-Arginine N-Methyltransferases, Repressor Proteins, Signal Transduction, Cell Line, Tumor, Mice, Heterografts, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.